Quality Tested Third-Party Verified Highly Purified U.S. Based Expert Support
PhysIQ PeptidesPhysIQ Peptides
Back to Shop
CJC-1295 (+DAC) 5mg research peptide vial

CJC-1295 (+DAC)

Modified Growth Hormone-Releasing Factor (1-29) with Drug Affinity Complex (DAC)

CJC-1295 with DAC (Drug Affinity Complex) is a modified synthetic 30-amino-acid analogue of growth hormone-releasing hormone (GHRH 1-29). It features specific amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) designed to resist enzymatic degradation, coupled with a reactive maleimidopropionic acid moiety at its C-terminal lysine residue. This chemical architecture facilitates covalent binding to endogenous serum albumin in research models, significantly extending its biological half-life.

In experimental laboratory settings, the peptide provides a continuous stimulus to anterior pituitary somatotrophs, resulting in prolonged elevations of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) levels. Unlike short-acting secretagogues, CJC-1295 with DAC supports research into chronic neuroendocrine regulation while preserving physiological pulsatile secretion characteristics.

This material is provided as a purified, lyophilized solid strictly intended for in vitro cellular assays and in vivo laboratory animal research exploring somatotropic signaling, metabolic modulation, and bioconjugate pharmacokinetics.

Choose how to buy

Your first order ships at the regular price. Every reship after that is 5% off. Pause, change the interval, or cancel anytime.

$65.00per vial · 5mg
Ask a Question
Third-party tested · Purity ≥99% · For laboratory research use only.
Purity
≥99%
Form
Lyophilized powder
CAS Number
863288-34-0
Molecular Formula
C152H252N44O42
Molecular Weight
3647.28 g/mol
Available sizes
5mg

Sequence

Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2

Mechanism of Action

CJC-1295 with DAC functions as a selective agonist at the growth hormone-releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs. Binding stimulates the Gs protein-coupled receptor cascade, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This signaling pathway opens voltage-dependent calcium channels, facilitating the gene transcription and secretory release of endogenous growth hormone.

The integrated Drug Affinity Complex contains a maleimide group that selectively binds to free thiol groups on circulating albumin (primarily cysteine-34). This bioconjugation shields the core peptide from rapid renal filtration and enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP), extending receptor engagement from minutes to multiple days in test subjects.

Research Areas

  • ●Pituitary somatotroph receptor kinetics
  • ●Long-acting peptide bioconjugation and pharmacokinetics
  • ●Endocrine regulation of systemic IGF-1 production
  • ●Adipocyte lipolysis and cellular metabolism models
  • ●Musculoskeletal tissue repair and protein synthesis pathways

Selected References

  • Teichman SL et al., J Clin Endocrinol Metab (2006)
  • Jette L et al., Endocrinology (2005)
  • Alba M et al., Am J Physiol Endocrinol Metab (2006)

Related Products

CJC-1295 No DAC research peptide vial

CJC-1295 No DAC

Purity
≥99%
Size
10mg
Form
Powder
$72.00Per Unit
Dihexa research peptide vial

Dihexa

Purity
≥99%
Size
10mg
Form
Powder
$97.00Per Unit
DSIP research peptide vial

DSIP

Purity
99%
Size
5mg
Form
Powder
$30.00Per Unit
Eloralintide research peptide vial

Eloralintide

Purity
≥99%
Size
10mg
Form
Powder
$228.00Per Unit